Polymeric nanoparticles in development for treatment of pulmonary infectious diseases

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 8, Issue 6, 2016, Pages 842-871

  Lim, Young H ^a   Tiemann, Kristin M ^b   Hunstad, David A ^b   Elsabahy, Mahmoud ^a,c,d   Wooley, Karen L ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ASSIUT UNIVERSITY   (Egypt)

^d MISR UNIVERSITY FOR SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL AGENTS; BIOLOGICAL ORGANS; DIAGNOSIS; FUNCTIONAL POLYMERS; NANOPARTICLES; NANOSTRUCTURES; POLYMERS;

DRUG-RESISTANT BACTERIA; INFECTIOUS DISEASE; POLYMERIC NANOPARTICLES; PULMONARY INFECTIONS; SURFACE CHARACTERISTICS; THERAPEUTIC AGENTS; THERAPEUTIC EFFICACY; THERAPEUTIC EFFICIENCY;

DISEASES;

ANTIBIOTIC AGENT; LIPID; MUCOLYTIC AGENT; NANOCARRIER; NANOMATERIAL; NANOPARTICLE; POLYMER; POLYMERIC NANOPARTICLE; SILVER NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; ERYTHROCYTE; HUMAN; HYBRID; HYDROPHOBICITY; LUNG; LUNG INFECTION; MUCUS; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; SURFACE PROPERTY; ANIMAL; NANOMEDICINE; PNEUMONIA, BACTERIAL; PROCEDURES; RAT; TUBERCULOSIS, PULMONARY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; PNEUMONIA, BACTERIAL; POLYMERS; RATS; TUBERCULOSIS, PULMONARY;

EID: 84961665324     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1401     Document Type: Review

References (178)

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004, 303:1818–1822. doi:10.1126/science.1095833.
2. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011, 469:483–490. doi:10.1038/nature09657.
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761–769. doi:10.1038/sj.clpt.6100400.
4. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24:1211–1217. doi:10.1038/nbt1006-1211.
5. Zhao F, Zhao Y, Liu Y, Chang X, Chen C. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011, 7:1322–1337. doi:10.1002/smll.201100001.
6. Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 2010, 62:284–304. doi:10.1016/j.addr.2009.11.002.
7. Elsabahy M, Wooley KL. Strategies toward well-defined polymer nanoparticles inspired by nature: chemistry versus versatility. J Polym Sci A Polym Chem 2012, 50:1869–1880. doi:10.1002/pola.25955.
8. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6:67–74. doi:10.1038/nrd2153.
9. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov 2005, 4:381–385. doi:10.1038/nrd1721.
10. Marco MD, Shamsuddin S, Razak KA, Aziz AA, Devaux C, Borghi E, Levy L, Sadun C. Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine 2010, 5:37–49. doi:10.2147/ijn.S6458.
11. Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine 2010, 5:287–306. doi:10.2217/nnm.09.110.
12. Chao P, Deshmukh M, Kutscher HL, Gao D, Rajan SS, Hu P, Laskin DL, Stein S, Sinko PJ. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs 2010, 21:65–76. doi:10.1097/cad.0b013e328332a322.
13. Koster VS, Kuks PFM, Lange R, Talsma H. Particle size in parenteral fat emulsions, what are the true limitations? Int J Pharm 1996, 134:235–238. doi:10.1016/0378-5173(95)04409-4.
14. Andrade F, Videira M, Ferreira D, Sarmento B. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine 2011, 6:123–141. doi:10.2217/nnm.10.143.
15. Bur M, Henning A, Hein S, Schneider M, Lehr C-M. Inhalative nanomedicine—opportunities and challenges. Inhal Toxicol 2009, 21(Suppl 1):137–143. doi:10.1080/08958370902962283.
16. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007, 25:563–570. doi:10.1016/j.tibtech.2007.09.005.
17. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1:338–344. doi:10.1513/pats.200409-049TA.
18. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008, 61:859–868. doi:10.1093/jac/dkn059.
19. Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 2003, 86:131–144. doi:10.1016/S0168-3659(02)00370-X.
20. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carr Syst 2002, 19:425–498. doi:10.1615/CritRevTherDrugCarrierSyst.v19.i45.40.
21. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008, 60:863–875. doi:10.1016/j.addr.2007.11.006.
22. Omlor A, Nguyen J, Bals R, Dinh QT. Nanotechnology in respiratory medicine. Respir Res 2015, 16:64. doi:10.1186/s12931-015-0223-5.
23. Kobayashi K, Wei J, Iida R, Ijiro K, Niikura K. Surface engineering of nanoparticles for therapeutic applications. Polym J 2014, 46:460–468. doi:10.1038/pj.2014.40.
24. Elsabahy M, Wooley K. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 2012, 41:2545–2561. doi:10.1039/c2cs15327k.
25. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev 2009, 61:115–127. doi:10.1016/j.addr.2008.09.011.
26. Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009, 61:158–171. doi:10.1016/j.addr.2008.11.002.
27. Lai SK, Wang YY, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv Drug Deliv Rev 2009, 61:86–100. doi:10.1016/j.addr.2008.09.012.
28. Petros R, DeSimone J. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615–627. doi:10.1038/nrd2591.
29. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469–478. doi:10.1038/nnano.2007.223.
30. Lee WH, Loo CY, Traini D, Young PM. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv 2015, 12:1009–1026. doi:10.1517/17425247.2015.1039509.
31. Griffiths G, Nystroem B, Sable SB, Khuller GK. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol 2010, 8:827–834. doi:10.1038/nrmicro2437.
32. Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev 2013, 42:5552–5576. doi:10.1039/c3cs60064e.
33. Champion J, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 2008, 25:1815–1821. doi:10.1007/s11095-008-9562-y.
34. Jiang W, Kim BYS, Rutka JT, Chan WCW. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3:145–150. doi:10.1038/nnano.2008.30.
35. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J 2004, 377:159–169. doi:10.1042/bj20031253.
36. Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Schaffler M, Takenaka S, Moller W, Schmid G, Simon U, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77:407–416. doi:10.1016/j.ejpb.2010.12.029.
37. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007, 121:3–9. doi:10.1016/j.jconrel.2007.03.022.
38. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2007, 2:249–255. doi:10.1038/nnao.2007.70.
39. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006, 103:4930–4934. doi:10.1073/pnas.0600997103.
40. Gessner A, Lieske A, Paulke BR, Müller RH. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm 2002, 54:165–170. doi:10.1016/S0939-6411(02)00081-4.
41. Gessner A, Waicz R, Lieske A, Paulke BR, Mäder K, Müller RH. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm 2000, 196:245–249. doi:10.1016/S0378-5173(99)00432-9.
42. Card JW, Zeldin DC, Bonner JC, Nestmann ER. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 2008, 295:L400–L411. doi:10.1152/ajplung.00041.2008.
43. Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008, 105:11613–11618. doi:10.1073/pnas.0801763105.
44. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater 2009, 8:15–23. doi:10.1038/nmat2344.
45. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res 2007, 24:411–437. doi:10.1007/s11095-006-9174-3.
46. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505–515. doi:10.1021/mp800051m.
47. Elsabahy M, Zhang S, Zhang F, Deng ZJ, Lim YH, Wang H, Parsamian P, Hammond PT, Wooley KL. Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles. Sci Rep 2013, 3. doi:10.1038/srep03313.
48. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 2010, 141:320–327. doi:10.1016/j.jconrel.2009.10.014.
49. Ilium L, Davis SS, Wilson CG, Thomas NW, Frier M, Hardy JG. Blood clearance and organ deposition of intravenously administered colloidal particles. the effects of particle size, nature and shape. Int J Pharm 1982, 12:135–146. doi:10.1016/0378-5173(82)90113-2.
50. Kutscher HL, Chao P, Deshmukh M, Singh Y, Hu P, Joseph LB, Reimer DC, Stein S, Laskin DL, Sinko PJ. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release 2010, 143:31–37. doi:10.1016/j.jconrel.2009.12.019.
51. Gao H, Xiong J, Cheng T, Liu J, Chu L, Ma R, Shi L. In vivo biodistribution of mixed shell micelles with tunable hydrophilic/hydrophobic surface. Biomacromolecules 2013, 14:460–467. doi:10.1021/bm301694t.
52. Sheng Y, Liu C, Yuan Y, Tao X, Yang F, Shan X, Zhou H, Xu F. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 2009, 30:2340–2348. doi:10.1016/j.biomaterials.2008.12.070.
53. Sasatsu M, Onishi H, Machida Y. Preparation and biodisposition of methoxypolyethylene glycol amine-poly(dl-lactic acid) copolymer nanoparticles loaded with pyrene-ended poly(dl-lactic acid). Int J Pharm 2008, 358:271–277. doi:10.1016/j.ijpharm.2008.03.011.
54. Sarlo K, Blackburn KL, Clark ED, Grothaus J, Chaney J, Neu S, Flood J, Abbott D, Bohne C, Casey K, et al. Tissue distribution of 20 nm, 100 nm and 1000 nm fluorescent polystyrene latex nanospheres following acute systemic or acute and repeat airway exposure in the rat. Toxicology 2009, 263:117–126. doi:10.1016/j.tox.2009.07.002.
55. Simon BH, Ando HY, Gupta PK. Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. J Pharm Sci 1995, 84:1249–1253. doi:10.1002/jps.2600841020.
56. Deshmukh M, Kutscher HL, Gao D, Sunil VR, Malaviya R, Vayas K, Stein S, Laskin JD, Laskin DL, Sinko PJ. Biodistribution and renal clearance of biocompatible lung targeted poly(ethylene glycol) (PEG) nanogel aggregates. J Control Release 2012, 164:65–73. doi:10.1016/j.jconrel.2012.09.011.
57. Pinkerton NM, Zhang SW, Youngblood RL, Gao D, Li S, Benson BR, Anthony J, Stone HA, Sinko PJ, Prud'homme RK. Gelation chemistries for the encapsulation of nanoparticles in composite gel microparticles for lung imaging and drug delivery. Biomacromolecules 2013, 15:252–261. doi:10.1021/bm4015232.
58. Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014, 75:81–91. doi:10.1016/j.addr.2014.05.017.
59. Son Y-J, McConville JT. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm 2008, 34:948–959. doi:10.1080/03639040802235902.
60. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 2009, 29:196–212. doi:10.1002/med.20140.
61. Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 2011, 63:441–455. doi:10.1016/j.addr.2010.11.002.
62. Rubin BK, Williams RW. Emerging aerosol drug delivery strategies: From bench to clinic. Adv Drug Deliv Rev 2014, 75:141–148. doi:10.1016/j.addr.2014.06.008.
63. Sanders NN, De Smedt SC, Van Rompaey E, Simoens P, De Baets F, Demeester J. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000, 162:1905–1911. doi:10.1164/ajrccm.162.5.9909009.
64. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem 2003, 278:50393–50401. doi:10.1074/jbc.m309026200.
65. Ensign LM, Henning A, Schneider CS, Maisel K, Wang YY, Porosoff MD, Cone R, Hanes J. Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm 2013, 10:2176–2182. doi:10.1021/mp400087y.
66. Kirch J, Guenther M, Doshi N, Schaefer UF, Schneider M, Mitragotri S, Lehr CM. Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge-an ex vivo and in silico approach. J Control Release 2012, 159:128–134. doi:10.1016/j.jconrel.2011.12.015.
67. Henning A, Schneider M, Nafee N, Muijs L, Rytting E, Wang XY, Kissel T, Grafahrend D, Klee D, Lehr CM. Influence of particle size and material properties on mucociliary clearance from the airways. J Aerosol Med Pulm Drug Deliv 2010, 23:233–241. doi:10.1089/jamp.2009.0806.
68. Liu Y, Ibricevic A, Cohen JA, Cohen JL, Gunsten SP, Fréchet JMJ, Walter MJ, Welch MJ, Brody SL. Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm 2009, 6:1891–1902. doi:10.1021/mp900215p.
69. Makino K, Yamamoto N, Higuchi K, Harada N, Ohshima H, Terada H. Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects of the size and surface properties of the microspheres. Colloids Surf B 2003, 27:33–39. doi:10.1016/S0927-7765(02)00042-5.
70. Roberts RA, Shen T, Allen IC, Hasan W, DeSimone JM, Ting JPY. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One 2013, 8:e62115. doi:10.1371/journal.pone.0062115.
71. Shen TW, Fromen CA, Kai MP, Luft JC, Rahhal TB, Robbins GR, DeSimone JM. Distribution and cellular uptake of PEGylated polymeric particles in the lung towards cell-specific targeted delivery. Pharm Res 2015, 32:3248–3260. doi:10.1007/s11095-015-1701-7.
72. Doshi N, Mitragotri S. Macrophages recognize size and shape of their targets. PLoS One 2010, 5:e10051. doi:10.1371/journal.pone.0010051.
73. Sharma G, Valenta DT, Altman Y, Harvey S, Xie H, Mitragotri S, Smith JW. Polymer particle shape independently influences binding and internalization by macrophages. J Control Release 2010, 147:408–412. doi:10.1016/j.jconrel.2010.07.116.
74. Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 2010, 28:1300–1303. doi:10.1038/nbt.1696.
75. Kreyling WG, Hirn S, Schleh C. Nanoparticles in the lung. Nat Biotechnol 2010, 28:1275–1276. doi:10.1038/nbt.1735.
76. Mohammad AK, Amayreh LK, Mazzara JM, Reineke JJ. Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration. Pharm Res 2013, 30:424–434. doi:10.1007/s11095-012-0884-4.
77. Ungaro F, d'Angelo I, Coletta C, d'Emmanuele di Villa Bianca R, Sorrentino R, Perfetto B, Tufano MA, Miro A, La Rotonda MI, Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012, 157:149–159. doi:10.1016/j.jconrel.2011.08.010.
78. Yang M, Lai SK, Yu T, Wang YY, Happe C, Zhong WX, Zhang M, Anonuevo A, Fridley C, Hung A, et al. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J Control Release 2014, 192:202–208. doi:10.1016/j.jconrel.2014.07.045.
79. Forier K, Messiaen AS, Raemdonck K, Deschout H, Rejman J, De Baets F, Nelis H, De Smedt SC, Demeester J, Coenye T, et al. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine 2013, 8:935–949. doi:10.2217/nnm.12.129.
80. Chen EYT, Wang YC, Chen CS, Chin WC. Functionalized positive nanoparticles reduce mucin swelling and dispersion. PLoS One 2010, 5:e15434. doi:10.1371/journal.pone.0015434.
81. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011, 6:715–728. doi:10.2217/nnm.11.19.
82. Boylan NJ, Kim AJ, Suk JS, Adstamongkonkul P, Simons BW, Lai SK, Cooper MJ, Hanes J. Enhancement of airway gene transfer by DNA nanoparticles using a pH-responsive block copolymer of polyethylene glycol and poly-L-lysine. Biomaterials 2012, 33:2361–2371. doi:10.1016/j.biomaterials.2011.11.080.
83. Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013, 34:3439–3446. doi:10.1016/j.biomaterials.2013.01.064.
84. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, Zeitlin P, Boyle MP, Fu J, Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009, 106:19268–19273. doi:10.1073/pnas.0905998106.
85. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R, Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007, 104:1482–1487. doi:10.1073/pnas.0608611104.
86. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591–2597. doi:10.1016/j.biomaterials.2008.12.076.
87. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew Chem Int Ed 2008, 47:9726–9729. doi:10.1002/anie.200803526.
88. Suk JS, Kim AJ, Trehan K, Schneider CS, Cebotaru L, Woodward OM, Boylan NJ, Boyle MP, Lai SK, Guggino WB, et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release 2014, 178:8–17. doi:10.1016/j.jconrel.2014.01.007.
89. Kleemann E, Jekel N, Dailey LA, Roesler S, Fink L, Weissmann N, Schermuly R, Gessler T, Schmehl T, Roberts CJ, et al. Enhanced gene expression and reduced toxicity in mice using polyplexes of low-molecular-weight poly(ethylene imine) for pulmonary gene delivery. J Drug Target 2009, 17:638–651. doi:10.1080/10611860903106414.
90. Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm 2009, 6:173–181. doi:10.1021/mp8001254.
91. Boylan NJ, Suk JS, Lai SK, Jelinek R, Boyle MP, Cooper MJ, Hanes J. Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release 2012, 157:72–79. doi:10.1016/j.jconrel.2011.08.031.
92. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006, 112:15–25. doi:10.1016/j.jconrel.2006.01.005.
93. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2012, 64:246–255. doi:10.1016/j.addr.2012.09.022.
94. Gallon AM. Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Thorax 1996, 51:429–432. doi:10.1136/thx.51.4.429.
95. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007, 8:24–29. doi:10.1016/j.prrv.2007.02.009.
96. Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine 2011, 6:365–375. doi:10.2217/nnm.10.123.
97. Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin JMG, Boyle MP, Zeitlin PL, Lai SK, Cooper MJ, et al. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther 2011, 19:1981–1989. doi:10.1038/mt.2011.160.
98. Schuster BS, Kim AJ, Kays JC, Kanzawa MM, Guggino WB, Boyle MP, Rowe SM, Muzyczka N, Suk JS, Hanes J. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther 2014, 22:1484–1493. doi:10.1038/mt.2014.89.
99. Mehanna MM, Mohyeldin SM, Elgindy NA. Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J Control Release 2014, 187:183–197. doi:10.1016/j.jconrel.2014.05.038.
100. Zhang F, Zhang S, Pollack SF, Li R, Gonzalez AM, Fan J, Zou J, Leininger SE, Pavía-Sanders A, Johnson R, et al. Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. J Am Chem Soc 2015, 137:2056–2066. doi:10.1021/ja512616s.
101. Aweda TA, Zhang S, Mupanomunda C, Burkemper J, Heo GS, Bandara N, Lin M, Cutler CS, Cannon CL, Youngs WJ, et al. Investigating the pharmacokinetics and biological distribution of silver-loaded polyphosphoester-based nanoparticles using 111Ag as a radiotracer. J Labelled Comp Radiopharm 2015, 58:234–241. doi:10.1002/jlcr.3289.
102. Shah PN, Lin LY, Smolen JA, Tagaev JA, Gunsten SP, Han DS, Heo GS, Li Y, Zhang F, Zhang S, et al. Synthesis, characterization, and in vivo efficacy of shell cross-linked nanoparticle formulations carrying silver antimicrobials as aerosolized therapeutics. ACS Nano 2013, 7:4977–4987. doi:10.1021/nn400322f.
103. Mura S, Hillaireau H, Nicolas J, Kerdine-Römer S, Le Droumaguet B, Deloménie C, Nicolas V, Pallardy M, Tsapis N, Fattal E. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 2011, 12:4136–4143. doi:10.1021/bm201226x.
104. Menon JU, Ravikumar P, Pise A, Gyawali D, Hsia CCW, Nguyen KT. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater 2014, 10:2643–2652. doi:10.1016/j.actbio.2014.01.033.
105. Choi M, Cho M, Han BS, Hong J, Jeong J, Park S, Cho M-H, Kim K, Cho W-S. Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol Lett 2010, 199:144–152. doi:10.1016/j.toxlet.2010.08.016.
106. Hara K, Tsujimoto H, Tsukada Y, Huang CC, Kawashima Y, Tsutsumi M. Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 2008, 356:267–273. doi:10.1016/j.ijpharm.2007.12.041.
107. Dombu CY, Kroubi M, Zibouche R, Matran R, Betbeder D. Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology 2010, 21:355102. doi:10.1088/0957-4484/21/35/355102.
108. Lai SK, Hida K, Man ST, Chen C, Machamer C, Schroer TA, Hanes J. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials 2007, 28:2876–2884. doi:10.1016/j.biomaterials.2007.02.021.
109. Lühmann T, Rimann M, Bittermann AG, Hall H. Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjugate Chem 2008, 19:1907–1916. doi:10.1021/bc800206r.
110. Ibricevic A, Guntsen SP, Zhang K, Shrestha R, Liu Y, Sun JY, Welch MJ, Wooley KL, Brody SL. PEGylation of cationic, shell-crosslinked-knedel-like nanoparticles modulates inflammation and enhances cellular uptake in the lung. Nanomedicine 2013, 9:912–922. doi:10.1016/j.nano.2013.02.006.
111. Kim AJ, Boylan NJ, Suk JS, Lai SK, Hanes J. Non-degradative intracellular trafficking of highly compacted polymeric DNA nanoparticles. J Control Release 2012, 158:102–107. doi:10.1016/j.jconrel.2011.10.031.
112. Kemp SJ, Thorley AJ, Gorelik J, Seckl MJ, O'Hare MJ, Arcaro A, Korchev Y, Goldstraw P, Tetley TD. Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. Am J Respir Cell Mol Biol 2008, 39:591–597. doi:10.1165/rcmb.2007-0334oc.
113. Dailey LA, Kleemann E, Wittmar M, Gessler T, Schmehl T, Roberts C, Seeger W, Kissel T. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 2003, 20:2011–2020. doi:10.1023/b:pham.0000008051.94834.10.
114. Harush-Frenkel O, Bivas-Benita M, Nassar T, Springer C, Sherman Y, Avital A, Altschuler Y, Borlak J, Benita S. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol Appl Pharm 2010, 246:83–90. doi:10.1016/j.taap.2010.04.011.
115. Grabowski N, Hillaireau H, Vergnaud J, Santiago LA, Kerdine-Romer S, Pallardy M, Tsapis N, Fattal E. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. Int J Pharm 2013, 454:686–694. doi:10.1016/j.ijpharm.2013.05.025.
116. Jones MC, Jones SA, Riffo-Vasquez Y, Spina D, Hoffman E, Morgan A, Patel A, Page C, Forbes B, Dailey LA. Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. J Control Release 2014, 183:94–104. doi:10.1016/j.jconrel.2014.03.022.
117. Valle RP, Huang CL, Loo JSC, Zuo YY. Increasing hydrophobicity of nanoparticles intensifies lung surfactant film inhibition and particle retention. ACS Sustain Chem Eng 2014, 2:1574–1580. doi:10.1021/sc500100b.
118. Hindi KM, Ditto AJ, Panzner MJ, Medvetz DA, Han DS, Hovis CE, Hilliard JK, Taylor JB, Yun YH, Cannon CL, et al. The antimicrobial efficacy of sustained release silver–carbene complex-loaded l-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies. Biomaterials 2009, 30:3771–3779. doi:10.1016/j.biomaterials.2009.03.044.
119. Kascatan Nebioglu A, Panzner M, Tessier C, Cannon C, Youngs W. N-heterocyclic carbene–silver complexes: a new class of antibiotics. Coord Chem Rev 2007, 251:884–895. doi:10.1016/j.ccr.2006.08.019.
120. Bjarnsholt T, Kirketerp-Moller K, Kristiansen S, Phipps R, Nielsen AK, Jensen PO, Hoiby N, Givskov M. Silver against Pseudomonas aeruginosa biofilms. APMIS 2007, 115:921–928. doi:10.1111/j.1600-0463.2007.apm_646.x.
121. Ornelas-Megiatto C, Shah PN, Wich PR, Cohen JL, Tagaev JA, Smolen JA, Wright BD, Panzner MJ, Youngs WJ, Fréchet JMJ, et al. Aerosolized antimicrobial agents based on degradable dextran nanoparticles loaded with silver carbene complexes. Mol Pharm 2012, 9:3012–3022. doi:10.1021/mp3004379.
122. Lim YH, Tiemann KM, Heo GS, Wagers PO, Rezenom YH, Zhang S, Zhang F, Youngs WJ, Hunstad DA, Wooley KL. Preparation and in vitro antimicrobial activity of silver-bearing degradable polymeric nanoparticles of polyphosphoester-block-poly(l-lactide). ACS Nano 2015, 9:1995–2008. doi:10.1021/nn507046h.
123. Zhang F, Smolen JA, Zhang S, Li R, Shah PN, Cho S, Wang H, Raymond JE, Cannon CL, Wooley KL. Degradable polyphosphoester-based silver-loaded nanoparticles as therapeutics for bacterial lung infections. Nanoscale 2015, 7:2265–2270. doi:10.1039/c4nr07103d.
124. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003, 83:373–378. doi:10.1016/j.tube.2003.07.001.
125. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003, 52:981–986. doi:10.1093/jac/dkg477.
126. Sung JC, Padilla DJ, Garcia-Contreras L, VerBerkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009, 26:1847–1855. doi:10.1007/s11095-009-9894-2.
127. Pandey R, Ahmad Z. Nanomedicine and experimental tuberculosis: facts, flaws, and future. Nanomedicine 2011, 7:259–272. doi:10.1016/j.nano.2011.01.009.
128. Lawlor C, Kelly C, O'Leary S, O'Sullivan MP, Gallagher PJ, Keane J, Cryan SA. Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of MTb. Tuberculosis 2011, 91:93–97. doi:10.1016/j.tube.2010.12.001.
129. de Faria TJ, Roman M, de Souza NM, De Vecchi R, de Assis JV, dos Santos ALG, Bechtold IH, Winter N, Soares MJ, Silva LP, et al. An isoniazid analogue promotes mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob Agents Chemother 2012, 56:2259–2267. doi:10.1128/aac.05993-11.
130. Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 2013, 85:427–443. doi:10.1016/j.ejpb.2013.07.002.
131. Chono S, Tanino T, Seki T, Morimoto K. Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 2006, 14:557–566. doi:10.1080/10611860600834375.
132. Cheow WS, Chang MW, Hadinoto K. The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf A 2011, 389:158–165. doi:10.1016/j.colsurfa.2011.08.035.
133. Liu G, Li DS, Pasumarthy MK, Kowalczyk TH, Gedeon CR, Hyatt SL, Payne JM, Miller TJ, Brunovskis P, Fink TL, et al. Nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem 2003, 278:32578–32586. doi:10.1074/jbc.M305776200.
134. Ziady AG, Gedeon CR, Miller T, Quan W, Payne JM, Hyatt SL, Fink TL, Muhammad O, Oette S, Kowalczyk T, et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003, 8:936–947. doi:10.1016/j.ymthe.2003.07.007.
135. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005, 4:581–593. doi:10.1038/nrd1775.
136. Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano 2012, 6:4279–4287. doi:10.1021/nn3008383.
137. El-Sherbiny IM, McGill S, Smyth HDC. Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci 2010, 99:2343–2356. doi:10.1002/jps.22003.
138. El-Sherbiny IM, Smyth HDC. Novel cryomilled physically cross-linked biodegradable hydrogel microparticles as carriers for inhalation therapy. J Microencapsul 2010, 27:657–668. doi:10.3109/02652041003739840.
139. Wanakule P, Liu GW, Fleury AT, Roy K. Nano-inside-micro: disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J Control Release 2012, 162:429–437. doi:10.1016/j.jconrel.2012.07.026.
140. Xiong M-H, Bao Y, Yang X-Z, Wang Y-C, Sun B, Wang J. Lipase-sensitive polymeric triple-layered nanogel for “on-demand” drug delivery. J Am Chem Soc 2012, 134:4355–4362. doi:10.1021/ja211279u.
141. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004, 54:761–766. doi:10.1093/jac/dkh411.
142. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des 2010, 16:2298–2307. doi:10.2174/138161210791920496.
143. Anselmo AC, Gupta V, Zern BJ, Pan D, Zakrewsky M, Muzykantov V, Mitragotri S. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 2013, 7:11129–11137. doi:10.1021/nn404853z.
144. Chambers E, Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Control Release 2004, 100:111–119. doi:10.1016/j.jconrel.2004.08.005.
145. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, Eberbeck D, Bittmann I, Bergemann C, Weyh T, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007, 2:495–499. doi:10.1038/nnano.2007.217.
146. Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov 2015, 14:239–247. doi:10.1038/nrd4503.
147. Rajendran L, Knölker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov 2010, 9:29–42. doi:10.1038/nrd2897.
148. Ding BS, Dziubla T, Shuvaev VV, Muro S, Muzykantov VR. Advanced drug delivery systems that target the vascular endothelium. Mol Interv 2006, 6:98–112. doi:10.1124/mi.6.2.7.
149. Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. WIREs Nanomed Nanobiotechnol 2011, 3:421–437. doi:10.1002/wnan.143.
150. Massey KA, Schnitzer JE. Targeting and imaging signature caveolar molecules in lungs. Proc Am Thorac Soc 2009, 6:419–430. doi:10.1513/pats.200903-011aw.
151. Oh P, Borgström P, Witkiewicz H, Li Y, Borgström BJ, Chrastina A, Iwata K, Zinn KR, Baldwin R, Testa JE, et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 2007, 25:327–337. doi:10.1038/nbt1292.
152. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006, 533:341–350. doi:10.1016/j.ejphar.2005.12.068.
153. Kudo K, Sano H, Takahashi H, Kuronuma K, Yokota SI, Fujii N, Shimada KI, Yano I, Kumazawa Y, Voelker DR, et al. Pulmonary collectins enhance phagocytosis of mycobacterium avium through increased activity of mannose receptor. J Immunol 2004, 172:7592–7602. doi:10.4049/jimmunol.172.12.7592.
154. Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008, 127:50–58. doi:10.1016/j.jconrel.2007.12.011.
155. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res 2009, 26:244–249. doi:10.1007/s11095-008-9626-z.
156. Anselmo AC, Kumar S, Gupta V, Pearce AM, Ragusa A, Muzykantov V, Mitragotri S. Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: synergy between physical, chemical and biological approaches. Biomaterials 2015, 68:1–8. doi:10.1016/j.biomaterials.2015.07.043.
157. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 2008, 16:1450–1458. doi:10.1038/mt.2008.127.
158. Nemmar A, Hoylaerts MF, Hoet PHM, Vermylen J, Nemery B. Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharm 2003, 186:38–45. doi:10.1016/S0041-008X(02)00024-8.
159. Hadinoto K, Cheow WS. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf B 2014, 116:772–785. doi:10.1016/j.colsurfb.2014.02.032.
160. Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, et al. Antimicrobial efficacy of tobramycin polymeric nanoparticles for pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). J Control Release 2015, 198:55–61. doi:10.1016/j.jconrel.2014.11.022.
161. Broughton-Head VJ, Smith JR, Shur J, Shute JK. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther 2007, 20:708–717. doi:10.1016/j.pupt.2006.08.008.
162. Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, Seeger W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharm 2006, 215:100–108. doi:10.1016/j.taap.2006.01.016.
163. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm 2009, 382:198–204. doi:10.1016/j.ijpharm.2009.07.023.
164. Houchin ML, Heppert K, Topp EM. Deamidation, acylation and proteolysis of a model peptide in PLGA films. J Control Release 2006, 112:111–119. doi:10.1016/j.jconrel.2006.01.018.
165. Dailey LA, Wittmar M, Kissel T. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J Control Release 2005, 101:137–149. doi:10.1016/j.jconrel.2004.09.003.
166. Wang XY, Xie XL, Cai CF, Rytting E, Steele T, Kissel T. Biodegradable branched polyesters poly(vinyl sulfonate-covinyl alcohol)-graft poly(D,L-lactic-coglycolic acid) as a negatively charged polyelectrolyte platform for drug delivery: synthesis and characterization. Macromolecules 2008, 41:2791–2799. doi:10.1021/ma702705s.
167. Fiore VF, Lofton MC, Roser-Page S, Yang SC, Roman J, Murthy N, Barker TH. Polyketal microparticles for therapeutic delivery to the lung. Biomaterials 2010, 31:810–817. doi:10.1016/j.biomaterials.2009.09.100.
168. Fiegel J, Fu J, Hanes J. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release 2004, 96:411–423. doi:10.1016/j.jconrel.2004.02.018.
169. Fu J, Fiegel J, Krauland E, Hanes J. New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials 2002, 23:4425–4433. doi:10.1016/s0142-9612(02)00182-5.
170. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, Kelly PM, Aberg C, Mahon E, Dawson KA. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013, 8:137–143. doi:10.1038/nnano.2012.237.
171. Behzadi S, Serpooshan V, Sakhtianchi R, Müller B, Landfester K, Crespy D, Mahmoudi M. Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface. Colloids Surf B 2014, 123:143–149. doi:10.1016/j.colsurfb.2014.09.009.
172. Ritz S, Schöttler S, Kotman N, Baier G, Musyanovych A, Kuharev J, Landfester K, Schild H, Jahn O, Tenzer S, et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 2015, 16:1311–1321. doi:10.1021/acs.biomac.5b00108.
173. Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, Schlenk F, Fischer D, Kiouptsi K, Reinhardt C, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 2013, 8:772–781. doi:10.1038/nnano.2013.181.
174. Winzen S, Schoettler S, Baier G, Rosenauer C, Mailaender V, Landfester K, Mohr K. Complementary analysis of the hard and soft protein corona: sample preparation critically effects corona composition. Nanoscale 2015, 7:2992–3001. doi:10.1039/c4nr05982d.
175. Kang B, Okwieka P, Schöttler S, Winzen S, Langhanki J, Mohr K, Opatz T, Mailänder V, Landfester K, Wurm FR. Carbohydrate-based nanocarriers exhibiting specific cell targeting with minimum influence from the protein corona. Angew Chem Int Ed 2015, 54:7436–7440. doi:10.1002/anie.201502398.
176. Wu Y, Ng DYW, Kuan SL, Weil T. Protein-polymer therapeutics: a macromolecular perspective. Biomater Sci 2015, 3:214–230. doi:10.1039/c4bm00270a.
177. Gauthier MA, Klok H-A. Polymer-protein conjugates: an enzymatic activity perspective. Polym Chem 2010, 1:1352–1373. doi:10.1039/c0py90001j.
178. Cobo I, Li M, Sumerlin BS, Perrier S. Smart hybrid materials by conjugation of responsive polymers to biomacromolecules. Nat Mater 2015, 14:143–149. doi:10.1038/nmat4106.